Patients from 22+ countriesPlan your visit →
lutetium-therapy
Considering Lu-177 Therapy · 23 Jul 2026

GEP-NET Types and When Lu-177 DOTATATE Is the Next Step

GEP-NETs are rare cancers of the gut and pancreas that often go undiagnosed for years. Learn what types exist, how tumor grade and somatostatin receptor expression shape your options, and when Lu-177 DOTATATE PRRT may be the right next step.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 23 Jul 2026
GEP-NET Types and When Lu-177 DOTATATE Is the Next Step

DOTATATE track - for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and their families.

This article covers the DOTATATE track. It is written for patients who have been diagnosed with a gastroenteropancreatic neuroendocrine tumor - a GEP-NET - including midgut carcinoid tumors, pancreatic NETs, and related types, and for the family members helping them find answers.

For many people with a GEP-NET, the diagnosis comes after years of unexplained symptoms. Flushing. Diarrhea. Stomach cramps that come and go. By the time a NET is confirmed, the tumor may have been growing quietly for a decade. Once you know you have a NET, your next question is often urgent: what do I do now?

Peptide receptor radionuclide therapy - PRRT - has helped many patients with advanced GEP-NETs. The drug used is called lutetium Lu 177 dotatate (brand name: Lutathera). But PRRT is not right for every patient. To know when to consider it, you need to understand what kind of tumor you have.

What is a neuroendocrine tumor?

Neuroendocrine cells are found throughout the body. Their job is to receive signals from the nervous system and release hormones in response. Most of these cells live in the gut, the lungs, and the pancreas. A neuroendocrine tumor (NET) forms when one of these cells starts to divide without stopping.

According to the American Cancer Society, the rate of GI neuroendocrine tumor diagnoses has increased significantly in recent decades - partly because better imaging now catches tumors that earlier tools would have missed.

One key feature of NETs is how slowly they tend to grow. A Grade 1 NET may take years to reach a size that causes clear symptoms. Even after it has spread to the liver, many patients feel reasonably well for a long time. This slow growth is one reason NETs are often found late - and it is also why certain targeted treatments, including PRRT, can help control tumors for months or years.

What makes a GEP-NET different from other NETs?

GEP-NET stands for gastroenteropancreatic neuroendocrine tumor. The name describes where the tumor started: somewhere in the digestive tract or the pancreas. These are the most common NETs in adults.

Within the GEP-NET family, the most common subtypes are:

  • Midgut NETs (historically called carcinoid tumors): These start in the small intestine or appendix. They often produce serotonin. When these hormones reach the bloodstream - usually after the tumor has spread to the liver - they can trigger carcinoid syndrome: skin flushing, watery diarrhea, wheezing, and sometimes changes to the heart valves over time.
  • Pancreatic NETs (pNETs): These form in the pancreas. Functional pNETs release hormones such as insulin, gastrin, or glucagon, causing distinct symptoms tied to each. Non-functional pNETs release no hormones and are often found late, only after they have grown large or spread.
  • Gastric and rectal NETs: These form in the stomach or rectum. Many are found incidentally during endoscopy. Treatment depends on size, grade, and depth of invasion.

The type of GEP-NET you have - where it started, whether it releases hormones, and which proteins it carries on its surface - shapes which treatments are available and how likely they are to work.

Why does your tumor grade matter?

After your biopsy, a pathologist assigned your tumor a grade. For NETs, grade is based on how quickly the cancer cells are dividing. The standard measure is the Ki-67 index: the percentage of tumor cells actively dividing at any given moment. The WHO classification uses three grades:

  • Grade 1 (G1): Ki-67 of 3% or less. These tumors grow very slowly.
  • Grade 2 (G2): Ki-67 between 3% and 20%. These grow at a moderate rate.
  • Grade 3 (G3): Ki-67 above 20%. These grow more quickly. G3 well-differentiated NETs are different from poorly differentiated neuroendocrine carcinomas, which grow faster and are managed differently.

Grade affects your eligibility for PRRT. The evidence for lutetium Lu 177 dotatate is strongest in G1 and G2 tumors, because lower-grade tumors tend to carry more somatostatin receptors on their surface - and those receptors are what PRRT targets. Your grade, your scan results, your stage, and your prior treatments all determine whether PRRT is right for you.

What role do somatostatin receptors play?

Somatostatin is a natural hormone your body makes. Many GEP-NETs carry a protein on their cell surface called the somatostatin receptor - particularly subtype 2 (SSTR2). This receptor acts as a docking port. Drugs that copy somatostatin - called somatostatin analogues, or SSAs - bind to this receptor and can slow tumor growth while reducing hormone-related symptoms.

The two most commonly used SSAs are octreotide (Sandostatin LAR) and lanreotide (Somatuline). They are usually the first treatment offered for somatostatin-receptor-positive GEP-NETs. For many patients, SSAs control the tumor and reduce symptoms for a long time. But tumors can eventually start growing again despite SSA therapy. When tumors start growing again, PRRT often becomes an option.

Before PRRT is considered, your team needs to confirm that your tumor still carries somatostatin receptors in sufficient quantity. This is done through a Ga-68 DOTATATE PET scan - a specialized imaging study that shows where tumor deposits sit and how strongly each site expresses the receptor. Our full guide on how Ga-68 DOTATATE PET determines your PRRT eligibility explains what to expect from this scan and how to read the results.

How does Lu-177 DOTATATE work?

Lutetium Lu 177 dotatate is a radioligand therapy. It pairs two elements: a radioactive isotope called lutetium-177 and a targeting molecule called dotatate, which binds to SSTR2 receptors on tumor cells. After injection, the drug travels through the bloodstream, attaches to receptor-bearing tumor cells, and emits radiation that damages those cells from within.

This targeted approach differs from whole-body radiation or standard chemotherapy. Rather than exposing all tissues to radiation, the drug concentrates it at tumor sites that express the receptor. Some healthy tissue - particularly the kidneys and bone marrow - can still be affected, which is why kidney-protective amino acids are given alongside each infusion and why blood monitoring is part of every treatment cycle.

This treatment is part of a method called theranostics, where the same molecular target used in imaging is also used to deliver treatment. The Ga-68 DOTATATE PET scan that confirms receptor expression and the lutetium Lu 177 dotatate infusion both work on SSTR2. Our article on how Lu-177 DOTATATE targets somatostatin receptors covers the full mechanism.

What does the clinical evidence show?

The key trial for PRRT in GEP-NETs is the NETTER-1 study, which enrolled 229 patients with progressive, somatostatin-receptor-positive midgut NETs that had stopped responding to standard-dose octreotide. Patients received either lutetium Lu 177 dotatate plus octreotide or high-dose octreotide alone.

The results were impressive. According to the National Cancer Institute, the estimated progression-free survival rate at 20 months was 65.2% in the lutetium Lu 177 dotatate group, compared with 10.8% in the high-dose octreotide group. The objective response rate - the percentage of patients whose tumors measurably shrank - was 18% with PRRT versus 3% in the control group.

Based on this evidence, the US Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera) in January 2018 for progressive, well-differentiated, locally advanced or metastatic, somatostatin receptor-positive GEP-NETs in adults. Research since then has continued to expand the evidence, including studies examining PRRT earlier in the treatment sequence and in patients with higher-grade tumors.

Who is a good candidate for Lu-177 DOTATATE?

Eligibility for PRRT depends on several factors:

  • Tumor type and grade: The strongest evidence supports PRRT in well-differentiated G1 and G2 GEP-NETs.
  • Somatostatin receptor uptake: Strong uptake across tumor sites on your Ga-68 DOTATATE PET scan is essential. Low or absent uptake suggests PRRT is unlikely to help.
  • Prior treatment: The standard pathway is after progression on SSA therapy. If SSAs are still controlling your tumor, your team may advise waiting before switching. Our article on when to switch from somatostatin analogues to Lu-177 DOTATATE breaks down how that decision is made.
  • Kidney function: The kidneys clear the drug and absorb some radiation. Baseline kidney function must be adequate to tolerate four cycles safely.
  • Bone marrow reserve: PRRT can cause temporary drops in white blood cells and platelets. Your team will check blood counts before each infusion.
  • Liver tumor burden: A large proportion of liver replaced by tumor may affect both safety and expected response.
  • General fitness: You need to be well enough to attend four sessions spaced roughly eight weeks apart and tolerate several hours per visit.

If you want a specialist to review your scans, pathology, and treatment history before deciding on a direction, you can request a Lu-177 eligibility review through Art of Healing Cancer. The nuclear-medicine team there can assess your case and tell you whether PRRT is a realistic option - or help you understand what alternatives to discuss if it is not.

What does a course of PRRT involve?

The standard treatment course with lutetium Lu 177 dotatate involves four infusion cycles, each spaced approximately eight weeks apart. Each infusion is given intravenously at a hospital or specialist center with nuclear-medicine facilities.

On each treatment day, you also receive an intravenous amino acid solution alongside the therapy drug. The amino acids help reduce the kidneys' radiation exposure. The session itself takes several hours. Most patients go home the same day or the following morning, depending on the center's protocol and your health at that point in treatment.

For a few days after each cycle, radiation precautions apply. You should limit sustained close contact with young children and pregnant women. Your treatment center will give you specific guidance based on your situation and the amount of activity measured at discharge.

Side effects vary but commonly include nausea, fatigue, and temporary changes in blood counts. Many patients also experience disrupted sleep in the days following each infusion. If you are looking for gentle, non-prescription sleep support during treatment, it may be worth exploring Ayurnomics's Sleep and Stress range of Ayurvedic formulations - but always check with your oncology team first before adding any supplement to your routine.

What if PRRT is not the right fit for your case?

Not every GEP-NET patient will be eligible. If your Ga-68 DOTATATE PET scan shows low somatostatin receptor expression, or if your kidney or bone marrow function is not sufficient to support four cycles, PRRT may not be appropriate for your situation. That is not the end of the road.

Other options depend on your specific tumor type, grade, and stage. For pancreatic NETs, targeted therapies such as everolimus or sunitinib have established evidence in certain settings. Liver-directed procedures are used for hepatic-dominant disease in some cases. Clinical trials are also actively enrolling NET patients in research exploring new treatment combinations and sequences.

If you are not sure whether you have received a complete picture of your options, a second opinion from a center that actively delivers PRRT can be helpful. Specialists who work with this therapy regularly see eligibility edge cases every week and may offer a perspective that has not yet been part of your conversation.

When to talk to your doctor

Speak with your oncologist or a NET specialist if any of the following apply: your GEP-NET has started progressing after SSA therapy; you have not yet had a Ga-68 DOTATATE PET scan; you have been told PRRT is not suitable but have not had a formal nuclear-medicine review; or you want to understand where PRRT fits in your overall plan before progression occurs. You can also submit your scans and pathology through the Lutetium Therapy contact form for an eligibility assessment. If PRRT turns out not to be the right fit, a second opinion on alternatives is part of that conversation too.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

What is the difference between a carcinoid tumor and a GEP-NET?

Carcinoid is an older term once used broadly for many slow-growing neuroendocrine tumors of the gut. Today, clinicians prefer more precise naming based on where the tumor started and its grade - for example, well-differentiated midgut NET rather than carcinoid. GEP-NET is the umbrella term covering all neuroendocrine tumors of the gastrointestinal tract and pancreas. If your records still say carcinoid, ask your oncologist which specific NET subtype and grade that refers to, because the distinction can affect treatment options.

Do I need a Ga-68 DOTATATE PET scan before I can be considered for PRRT?

Yes. A Ga-68 DOTATATE PET scan is the standard way to check whether your tumor carries the somatostatin receptors that lutetium Lu 177 dotatate targets. Without confirmed receptor expression on this scan, PRRT is unlikely to provide meaningful benefit. Most specialist centers require this imaging before scheduling treatment. If you have not had one yet, discussing it with your oncologist is a key first step.

How many cycles does a standard PRRT course involve?

The standard course of lutetium Lu 177 dotatate (Lutathera) involves four infusion cycles, each spaced approximately eight weeks apart. Each cycle is an intravenous infusion at a hospital or nuclear-medicine center. Your team monitors kidney function and blood counts between cycles to confirm it is safe to continue.

Can I still receive Lu-177 DOTATATE if my NET is Grade 3?

The NETTER-1 trial that supported FDA approval focused on Grade 1 and Grade 2, well-differentiated tumors. Grade 3 well-differentiated NETs are a distinct category from poorly differentiated neuroendocrine carcinomas, and research into PRRT for G3 NETs is ongoing. If your tumor is Grade 3, a specialist review from a nuclear-medicine team with active PRRT experience is needed to assess whether DOTATATE scan uptake and other factors make PRRT a reasonable option for your specific case.

What options are available if PRRT is not suitable for me?

If PRRT is ruled out because of low receptor uptake, insufficient kidney function, or other factors, other treatments may be available depending on your tumor type and stage. For pancreatic NETs, targeted therapies such as everolimus or sunitinib have established evidence in certain settings. Liver-directed procedures, chemotherapy for some higher-grade tumors, and clinical trials are also used. A second opinion from a NET specialist can help map out which alternatives apply to your situation.

Is PRRT available in India for international patients?

Yes. Lutetium Lu 177 dotatate therapy is offered at specialist centers in India, often at significantly lower cost than in the US, UK, or UAE. Many patients from GCC countries, Africa, and South Asia travel to India for PRRT. A remote eligibility review using your existing scans and pathology can usually be arranged before you travel, so you know whether PRRT is the right path before committing to the trip.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

GEP-NETs Explained: When Lu-177 DOTATATE PRRT Is Right | lutetium-therapy